LMPTP INHIBITOR 1 dihydrochloride ( —— )

产品货号. M28358 CAS No. 2310135-46-5

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

拼团产品询价大包装询价加入购物车

产品名称

LMPTP INHIBITOR 1 dihydrochloride
注意事项

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
产品简述

LMPTP INHIBITOR 1 dihydrochloride is a selective inhibitor of low molecular weight protein tyrosine phosphatase (LMPTP), with an?IC50?of 0.8 μM LMPTP-A.
产品描述

LMPTP INHIBITOR 1 dihydrochloride is a selective inhibitor of low molecular weight protein tyrosine phosphatase (LMPTP), with an?IC50?of 0.8 μM LMPTP-A.(In Vitro):LMPTP INHIBITOR 1 dihydrochloride is a selective inhibitor of low molecular weight protein tyrosine phosphatase, with an IC50?of 0.8 μM LMPTP-A and shows more potent effect on LMPTP-A versus LMPTP-B. LMPTP inhibitor 1 dihydrochloride (10 μM) also enhances HepG2 IR phosphorylation after insulin stimulation in human HepG2 hepatocytes.(In Vivo):LMPTP inhibitor 1 dihydrochloride is orally bioavailable, and results in appr 680 nM mean serum concentration after treatment of 0.03% w/w, while treatment with 0.05% w/w results in >3 μM; also reverses diabetes in obese mice. LMPTP inhibitor 1 dihydrochloride (0.05% w/w) inhibits LMPTP activity, significantly improves glucose tolerance and decreases fasting insulin levels of diabetic DIO mice, without affecting body weight.
同义词

——
通路

Metabolic Enzyme/Protease
靶点

Phosphatase
受体

E3 Ligase Ligand-Linker Conjugate
研究领域

——
适应症

——

1.Qiu X, et al. Jiang B. Chemoselective Synthesis of Lenalidomide-Based PROTAC Library Using Alkylation Reaction. Org Lett. 2019;21(10):3838-3841.

计算器

产品手册

关联产品

PTP1B-IN-4

PTP1B-IN-4 is an allosteric PTP1B inhibitor with an IC50 of 8 μM. PTP1B-IN-4 can be used in studies about obesity and diabetes.
MHP

MHP is an activator of sphingosine kinase (SPHK1), and significantly stimulates CAMP mRNA and protein production in KC.
SHP099

SHP099 free base is an effective, selective, orally bioavailable, and efficacious SHP2 inhibitor (IC50 =0.07 μM and p-ERK modulation in cells IC50 = 0.250 μM). SHP099 shows dose-dependent pathway inhibition and antitumor activity in xenograft models.